Needham Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)

June 25, 2026 7:12 AM

Needham analyst Chad Messer reiterated a Buy rating and $105.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS).The analyst commented: "Yesterday ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found